Compare Repligen Corporation Common Stock (RGEN) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs BlackRock TCP Capital Corp — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while BlackRock TCP Capital Corp trades at $4.07 (market cap $342.32M). The key difference: Repligen Corporation Common Stock is far larger — about 33× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.63% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and BlackRock TCP Capital Corp for 89 Days on average.
| RGEN | TCPC | |
|---|---|---|
Market Cap | $11.31B | $342.32M |
Volume | 1,216,919 | 916,536 |
Sector | Health | Financials |
52-Week High | $194.57 | $6.20 |
52-Week Low | $102.87 | $3.13 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $11.20B | $1.10B |
Dividend Yield | — | 18.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TCPC trades at $3.98 with no recent price movement. The stock shows a bullish technical signal with strong moving average support, though oscillators remain neutral. Fundamentally, the company reported negative revenue and net income for 2025, with declining trends projected into 2026. Recent positive developments include Q2 2026 earnings beats and a $523 million portfolio sale that reduced leverage. Analyst sentiment is mixed with 30.77% buy ratings but 69.23% hold recommendations.
TCPC presents a complex investment case with attractive valuation metrics including P/B of 0.62 suggesting potential undervaluation, but significant fundamental challenges with negative revenue and profitability trends. The strategic portfolio sale and ongoing business review offer potential catalysts, though investors face risks from the class action lawsuit and persistent negative cash flow. The dividend yield remains a positive factor for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
